Lexicon Pharma (LXRX) Reports In-Line Q4 EPS
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.96 +3.70%
Revenue Growth %: -86.1%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: -86.1%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.16), in-line with the analyst estimate of ($0.16). Revenue for the quarter came in at $37 thousand versus the consensus estimate of $50 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist
- Independent Bank receives regulatory approval for HCB Financial acquisition
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
